Short Interest in Biorestorative Therapies, Inc. (NASDAQ:BRTX) Decreases By 80.6%

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,281,247 shares, a decrease of 80.6% from the May 31st total of 6,588,718 shares. Currently, 5.8% of the shares of the company are short sold. Based on an average daily trading volume, of 1,895,030 shares, the days-to-cover ratio is presently 0.7 days.

Biorestorative Therapies Trading Down 0.8%

Shares of Biorestorative Therapies stock opened at $0.39 on Friday. The firm has a market cap of $10.04 million, a PE ratio of -0.37 and a beta of 0.67. The stock has a 50 day moving average of $0.30 and a 200 day moving average of $0.56. Biorestorative Therapies has a 12 month low of $0.16 and a 12 month high of $1.89.

Biorestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.31 million. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. As a group, equities research analysts forecast that Biorestorative Therapies will post -0.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Biorestorative Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC grew its holdings in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares during the last quarter. DRW Securities LLC purchased a new stake in Biorestorative Therapies in the 4th quarter valued at about $55,000. Finally, Citadel Advisors LLC purchased a new position in shares of Biorestorative Therapies during the third quarter worth approximately $152,000. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.